Godalming, UK, 31 May 2007: In line with the Transparency Directive's
transitional provision 6, Sinclair Pharma plc (LSE: SPH) would like
to notify the market of the following:
The Company's issued share capital at 30 April 2007 consists of
93,421,219 ordinary shares with a nominal value of 1 pence per share,
with voting rights (one vote per ordinary share). The Company does
not hold any ordinary shares in Treasury.
Therefore, the total number of ordinary shares in the Company with
voting rights is 93,421,219.
The above figure of 93,421,219 ordinary shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Financial Service
Authority's Disclosure and Transparency Rules.
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Zoe McDougall, Director of Communications
Capital MS&L
Mary Clark, Halina Kukula Tel +44 (0)20 7307 5340
Notes to Editors:
About Sinclair Pharma Plc
www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical
company. It has a growing sales and marketing operation that is
already present in France, Italy, UK, Spain and Portugal, and a
complementary marketing partner network that spans more than 65
countries.
Sinclair has proven expertise in acquiring or developing commercially
attractive and undervalued products, registering these products and
bringing them to market within a short time frame. The company
focuses on niche therapeutic areas and its current portfolio includes
products for dermatological conditions and oral health.
---END OF MESSAGE---
